Expert consensus on the monitoring and treatment of sepsis-induced immunosuppression

[1]  J. Bian,et al.  How to improve the care of septic patients following “Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021”? , 2022, Journal of intensive medicine.

[2]  Yu Zhou,et al.  Lymphocyte trajectories are associated with prognosis in critically ill patients: A convenient way to monitor immune status , 2022, Frontiers in Medicine.

[3]  T. Billiar,et al.  Single-cell transcriptome profiling of the immune space-time landscape reveals dendritic cell regulatory program in polymicrobial sepsis , 2022, Theranostics.

[4]  R. Yao,et al.  Advances in Immune Monitoring Approaches for Sepsis-Induced Immunosuppression , 2022, Frontiers in Immunology.

[5]  C. Dupuis,et al.  Monitoring of circulating monocyte HLA-DR expression in a large cohort of intensive care patients: relation with secondary infections , 2022, Annals of Intensive Care.

[6]  Minying Chen,et al.  Thymosin alpha 1 therapy alleviates organ dysfunction of sepsis patients: a retrospective cohort study , 2022, Exploration of Immunology.

[7]  D. Maucort-Boulch,et al.  Monocyte Trajectories Endotypes Are Associated With Worsening in Septic Patients , 2021, Frontiers in Immunology.

[8]  G. Grasselli,et al.  Higher levels of IgA and IgG at sepsis onset are associated with higher mortality: results from the Albumin Italian Outcome Sepsis (ALBIOS) trial , 2021, Annals of Intensive Care.

[9]  M. Shankar-Hari,et al.  The immunology of sepsis. , 2021, Immunity.

[10]  T. van der Poll,et al.  Sepsis-Induced Immunosuppression. , 2021, Annual review of physiology.

[11]  C. Sprung,et al.  Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 , 2021, Intensive Care Medicine.

[12]  Hongzhou Lu,et al.  Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients , 2021, Frontiers in Immunology.

[13]  T. Rimmele,et al.  Longitudinal assessment of IFN-I activity and immune profile in critically ill COVID-19 patients with acute respiratory distress syndrome , 2021, Critical Care.

[14]  K. Brengel-Pesce,et al.  Differential response induced by LPS and MPLA in immunocompetent and septic individuals. , 2021, Clinical immunology.

[15]  H. Tamim,et al.  Sepsis in patients with haematological versus solid cancer: a retrospective cohort study , 2021, BMJ Open.

[16]  H. Okudera,et al.  Association between low body mass index and increased 28-day mortality of severe sepsis in Japanese cohorts , 2021, Scientific Reports.

[17]  Xiangjun Bai,et al.  The Trajectory of Alterations in Immune-Cell Counts in Severe-Trauma Patients Is Related to the Later Occurrence of Sepsis and Mortality: Retrospective Study of 917 Cases , 2021, Frontiers in Immunology.

[18]  Henry E. Wang,et al.  A Prospective Study of Community Mediators on the Risk of Sepsis After Cancer , 2020, Journal of intensive care medicine.

[19]  Yi Yang,et al.  The effect of thymosin α1 on mortality of critical COVID-19 patients: A multicenter retrospective study , 2020, International Immunopharmacology.

[20]  W. Guan,et al.  Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial. , 2020, JAMA internal medicine.

[21]  Zhengming Chen,et al.  Body-mass index and long-term risk of sepsis-related mortality: a population-based cohort study of 0.5 million Chinese adults , 2020, Critical Care.

[22]  Zhifeng Liu,et al.  Thymosin α1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study , 2020, International Immunopharmacology.

[23]  Minying Chen,et al.  Early Immunoparalysis Was Associated with Poor Prognosis in Elderly Patients with Sepsis: Secondary Analysis of the ETASS Study , 2020, Infection and drug resistance.

[24]  Zhenhong Hu,et al.  Thymosin alpha 1 (Tα1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  T. Rimmele,et al.  Monocytic HLA-DR expression kinetics in septic shock patients with different pathogens, sites of infection and adverse outcomes , 2020, Critical Care.

[26]  N. Hacohen,et al.  An immune-cell signature of bacterial sepsis , 2020, Nature Medicine.

[27]  S. Eiam‐Ong,et al.  The role of neutrophil chemotaxis activity as an immunologic biomarker to predict mortality in critically-ill patients with severe sepsis. , 2020, Journal of critical care.

[28]  Niranjan Kissoon,et al.  Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study , 2020, The Lancet.

[29]  M. Levy,et al.  Biomarkers of Immunosuppression. , 2020, Critical care clinics.

[30]  V. Pettilä,et al.  Time course of signaling profiles of blood leukocytes in acute pancreatitis and sepsis , 2019, Scandinavian journal of clinical and laboratory investigation.

[31]  M. Netea,et al.  Current gaps in sepsis immunology: new opportunities for translational research. , 2019, The Lancet. Infectious diseases.

[32]  R. Pirracchio,et al.  Neutropenic Enterocolitis in Critically Ill Patients: Spectrum of the Disease and Risk of Invasive Fungal Disease , 2019, Critical care medicine.

[33]  F. Guo,et al.  Early and dynamic alterations of Th2/Th1 in previously immunocompetent patients with community-acquired severe sepsis: a prospective observational study , 2019, Journal of Translational Medicine.

[34]  T. Sonoo,et al.  Single versus divided administration of intravenous immunoglobulin for sepsis: a retrospective and historical control study. , 2019, Minerva anestesiologica.

[35]  B. Heniford,et al.  Chronic immunosuppressant use in colorectal cancer patients worsens postoperative morbidity and mortality through septic complications in a propensity‐matched analysis , 2018, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[36]  W. F. Abdo,et al.  Precision Immunotherapy for Sepsis , 2018, Front. Immunol..

[37]  Q. Ma,et al.  Impact of body mass index on survival of medical patients with sepsis: a prospective cohort study in a university hospital in China , 2018, BMJ Open.

[38]  M. Béné,et al.  Multicentric Standardized Flow Cytometry Routine Assessment of Patients With Sepsis to Predict Clinical Worsening , 2018, Chest.

[39]  O. Ramilo,et al.  Early Immune Function and Duration of Organ Dysfunction in Critically III Children with Sepsis , 2018, American journal of respiratory and critical care medicine.

[40]  A. Conway Morris,et al.  Randomised controlled trial of GM-CSF in critically ill patients with impaired neutrophil phagocytosis , 2018, Thorax.

[41]  X. Guan,et al.  Thymosin alpha 1 treatment for patients with sepsis , 2018, Expert opinion on biological therapy.

[42]  M. Singer,et al.  Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study) , 2018, Intensive Care Medicine.

[43]  R. Hotchkiss,et al.  Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. , 2018, JCI insight.

[44]  F. Venet,et al.  Advances in the understanding and treatment of sepsis-induced immunosuppression , 2018, Nature Reviews Nephrology.

[45]  T. Rimmele,et al.  Assessment of sepsis-induced immunosuppression at ICU discharge and 6 months after ICU discharge , 2017, Annals of Intensive Care.

[46]  D. Tang,et al.  Th17/Regulatory T Cell Imbalance in Sepsis Patients with Multiple Organ Dysfunction Syndrome: Attenuated by High-volume Hemofiltration , 2017, The International journal of artificial organs.

[47]  Tsuyoshi Nakashima,et al.  Low-dose immunoglobulin G is not associated with mortality in patients with sepsis and septic shock , 2017, Critical Care.

[48]  Henry E. Wang,et al.  Association of baseline steroid use with long-term rates of infection and sepsis in the REGARDS cohort , 2017, Critical Care.

[49]  J. Lord,et al.  Neutrophil Dysfunction, Immature Granulocytes, and Cell-free DNA are Early Biomarkers of Sepsis in Burn-injured Patients: A Prospective Observational Cohort Study , 2017, Annals of surgery.

[50]  M. Singer,et al.  Activation-Associated Accelerated Apoptosis of Memory B Cells in Critically Ill Patients With Sepsis , 2017, Critical care medicine.

[51]  M. Netea,et al.  The immunopathology of sepsis and potential therapeutic targets , 2017, Nature Reviews Immunology.

[52]  T. Lange,et al.  Immunoglobulin G for patients with necrotising soft tissue infection (INSTINCT): a randomised, blinded, placebo-controlled trial , 2017, Intensive Care Medicine.

[53]  B. Souweine,et al.  Persistent lymphopenia is a risk factor for ICU-acquired infections and for death in ICU patients with sustained hypotension at admission , 2017, Annals of Intensive Care.

[54]  Hu Peng,et al.  Dynamic monitoring of monocyte HLA-DR expression for the diagnosis, prognosis, and prediction of sepsis. , 2017, Frontiers in bioscience.

[55]  C. Aldecoa,et al.  Sepsis and Immunosenescence in the Elderly Patient: A Review , 2017, Front. Med..

[56]  S. Bhoi,et al.  Coexistence of Th1/Th2 and Th17/Treg imbalances in patients with post traumatic sepsis. , 2016, Cytokine.

[57]  K. Brohi,et al.  Persistent lymphopenia is an independent predictor of mortality in critically ill emergency general surgical patients , 2016, European Journal of Trauma and Emergency Surgery.

[58]  R. Hotchkiss,et al.  Comparison of monocyte human leukocyte antigen-DR expression and stimulated tumor necrosis factor alpha production as outcome predictors in severe sepsis: a prospective observational study , 2016, Critical Care.

[59]  Tiansheng Wang,et al.  The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials , 2016, BMC Infectious Diseases.

[60]  Y. Kametani,et al.  Reduced Immunocompetent B Cells and Increased Secondary Infection in Elderly Patients With Severe Sepsis , 2016, Shock.

[61]  W. Göpel,et al.  Regulatory T cell frequencies are increased in preterm infants with clinical early‐onset sepsis , 2016, Clinical and experimental immunology.

[62]  T. van der Poll,et al.  Incidence, Risk Factors, and Attributable Mortality of Secondary Infections in the Intensive Care Unit After Admission for Sepsis. , 2016, JAMA.

[63]  Christopher W Seymour,et al.  Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[64]  J. Routy,et al.  Aging of immune system: Immune signature from peripheral blood lymphocyte subsets in 1068 healthy adults , 2016, Aging.

[65]  M. Delano,et al.  Sepsis-induced immune dysfunction: can immune therapies reduce mortality? , 2016, The Journal of clinical investigation.

[66]  A. Friggeri,et al.  Marked alterations of neutrophil functions during sepsis‐induced immunosuppression , 2015, Journal of leukocyte biology.

[67]  R. Dellinger,et al.  Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus. , 2015, Critical reviews in oncology/hematology.

[68]  Pan‐Chyr Yang,et al.  Severe Lymphopenia Is Associated with Elevated Plasma Interleukin-15 Levels and Increased Mortality During Severe Sepsis , 2015, Shock.

[69]  M. Singer,et al.  Endogenous IgG hypogammaglobulinaemia in critically ill adults with sepsis: systematic review and meta-analysis , 2015, Intensive Care Medicine.

[70]  L. Su,et al.  Alterations of T Helper Lymphocyte Subpopulations in Sepsis, Severe Sepsis, and Septic Shock: A Prospective Observational Study , 2014, Inflammation.

[71]  R. Hotchkiss,et al.  Persistent Lymphopenia After Diagnosis of Sepsis Predicts Mortality , 2014, Shock.

[72]  R. Herrán-Monge,et al.  Immunoglobulins IgG1, IgM and IgA: a synergistic team influencing survival in sepsis , 2014, Journal of internal medicine.

[73]  A. Ford,et al.  Neutropenic sepsis: a potentially life-threatening complication of chemotherapy. , 2014, Clinical medicine.

[74]  M. Hall,et al.  Early adaptive immune suppression in children with septic shock: a prospective observational study , 2014, Critical Care.

[75]  J. Chiche,et al.  Specific MAIT cell behaviour among innate-like T lymphocytes in critically ill patients with severe infections , 2014, Intensive Care Medicine.

[76]  R. Hotchkiss,et al.  Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy , 2013, Nature Reviews Immunology.

[77]  Hong-ping Qu,et al.  Increased proportion of CD4(+)CD25(+)Foxp3(+) regulatory T cells during early-stage sepsis in ICU patients. , 2013, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[78]  L. Dans,et al.  Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. , 2013, The Cochrane database of systematic reviews.

[79]  R. Hotchkiss,et al.  Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies. , 2013, Current opinion in immunology.

[80]  A. De La Hera,et al.  Early alterations of B cells in patients with septic shock , 2013, Critical Care.

[81]  J. Pugin,et al.  Innate Immune Functions of Immature Neutrophils in Patients With Sepsis and Severe Systemic Inflammatory Response Syndrome* , 2013, Critical care medicine.

[82]  R. Hotchkiss,et al.  Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. , 2013, The Lancet. Infectious diseases.

[83]  T. Chiba,et al.  Reduction of Immunocompetent T Cells Followed by Prolonged Lymphopenia in Severe Sepsis in the Elderly* , 2013, Critical care medicine.

[84]  Minying Chen,et al.  The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial , 2013, Critical Care.

[85]  L. Chiche,et al.  Phenotype and Functions of Natural Killer Cells in Critically-Ill Septic Patients , 2012, PloS one.

[86]  Henry E. Wang,et al.  Chronic Medical Conditions and Risk of Sepsis , 2012, PloS one.

[87]  R. Hotchkiss,et al.  A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis , 2012, Critical Care.

[88]  B. Allaouchiche,et al.  Early Interleukin-6 and Slope of Monocyte Human Leukocyte Antigen-DR: A Powerful Association to Predict the Development of Sepsis after Major Trauma , 2012, PloS one.

[89]  R. Hotchkiss,et al.  Immunosuppression in patients who die of sepsis and multiple organ failure. , 2011, JAMA.

[90]  F. Venet,et al.  A dynamic view of mHLA-DR expression in management of severe septic patients , 2011, Critical care.

[91]  A. Lin,et al.  Changes of monocyte human leukocyte antigen-DR expression as a reliable predictor of mortality in severe sepsis , 2011, Critical care.

[92]  J. Chiche,et al.  Profound and persistent decrease of circulating dendritic cells is associated with ICU-acquired infection in patients with septic shock , 2011, Intensive Care Medicine.

[93]  J. Carcillo,et al.  Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome , 2011, Intensive Care Medicine.

[94]  Fei Wang,et al.  Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis , 2011, Critical care.

[95]  D. Radolovich,et al.  Flow cytometric analysis of peripheral blood dendritic cells in patients with severe sepsis , 2011, Cytometry. Part B, Clinical cytometry.

[96]  B. Mougin,et al.  EARLY ASSESSMENT OF LEUKOCYTE ALTERATIONS AT DIAGNOSIS OF SEPTIC SHOCK , 2010, Shock.

[97]  T. Baumann,et al.  Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. , 2009, American journal of respiratory and critical care medicine.

[98]  C. Meisel,et al.  Phenotype changes and impaired function of dendritic cell subsets in patients with sepsis: a prospective observational analysis , 2009, Critical care.

[99]  C. Chung,et al.  Increased circulating regulatory T cells (CD4+CD25+CD127−) contribute to lymphocyte anergy in septic shock patients , 2009, Intensive Care Medicine.

[100]  Yan Yu,et al.  Low HLA-DR expression on CD14+ monocytes of burn victims with sepsis, and the effect of carbachol in vitro. , 2008, Burns : journal of the International Society for Burn Injuries.

[101]  F. Mohr,et al.  Immunoglobulin G treatment of postcardiac surgery patients with score-identified severe systemic inflammatory response syndrome—The ESSICS study* , 2008, Critical care medicine.

[102]  S. Sriskandan,et al.  The immunology of sepsis , 2008, The Journal of pathology.

[103]  R. Schmieder,et al.  Score‐based immunoglobulin G therapy of patients with sepsis: The SBITS study * , 2007, Critical care medicine.

[104]  A. Delaney,et al.  Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: A systematic review and meta‐analysis * , 2007, Critical care medicine.

[105]  K. Werdan.  Mirror, mirror on the wall, which is the fairest meta-analysis of all? , 2007, Critical care medicine.

[106]  G. Rasi,et al.  Thymosin α1 , 2007 .

[107]  Hong-yuan Lin.  [Clinical trial with a new immunomodulatory strategy: treatment of severe sepsis with Ulinastatin and Maipuxin]. , 2007, Zhonghua yi xue za zhi.

[108]  T. Tsaganos,et al.  Early changes of CD4-positive lymphocytes and NK cells in patients with severe Gram-negative sepsis , 2006, Critical care.

[109]  N. Voirin,et al.  Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock , 2006, Intensive Care Medicine.

[110]  D. Mannino,et al.  The epidemiology of sepsis in patients with malignancy. , 2006, Chest.

[111]  W. Hiddemann,et al.  IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: A randomized, controlled, multiple-center trial* , 2006, Critical care medicine.

[112]  H. Medina-Franco,et al.  Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, double-blind, placebo-controlled clinical trial. , 2006, Archives of surgery.

[113]  J. Johnston,et al.  Impact of HIV/AIDS on care and outcomes of severe sepsis , 2004, Critical care.

[114]  Joseph Johnston,et al.  Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care , 2004, Critical care.

[115]  J. Bienvenu,et al.  Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsis-induced immunoparalysis , 2003, Critical care medicine.

[116]  V. Pettilä,et al.  PREDICTIVE VALUE OF MONOCYTE HISTOCOMPATIBILITY LEUKOCYTE ANTIGEN‐DR EXPRESSION AND PLASMA INTERLEUKIN‐4 AND ‐10 LEVELS IN CRITICALLY ILL PATIENTS WITH SEPSIS , 2003, Shock.

[117]  B. Drénou,et al.  Early Circulating Lymphocyte Apoptosis in Human Septic Shock Is Associated with Poor Outcome , 2002, Shock.

[118]  C. Coopersmith,et al.  Depletion of Dendritic Cells, But Not Macrophages, in Patients with Sepsis , 2002, The Journal of Immunology.

[119]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.

[120]  R. Hotchkiss,et al.  Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans1 , 2001, The Journal of Immunology.

[121]  R. Hotchkiss,et al.  Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. , 1999, Critical care medicine.

[122]  T. Menges,et al.  Changes in blood lymphocyte populations after multiple trauma: association with posttraumatic complications. , 1999, Critical care medicine.

[123]  C. Natanson,et al.  Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. , 1997, Critical care medicine.

[124]  J. Cavaillon,et al.  Dysregulation of in vitro cytokine production by monocytes during sepsis. , 1991, The Journal of clinical investigation.

[125]  L. Su,et al.  Alterations of T Helper Lymphocyte Subpopulations in Sepsis, Severe Sepsis, and Septic Shock: A Prospective Observational Study , 2014, Inflammation.

[126]  M. Dostál,et al.  Presence of hypogammaglobulinemia - a risk factor of mortality in patients with severe sepsis, septic shock, and SIRS. , 2013, Prague medical report.

[127]  E. Roth,et al.  Lipopolysaccharide-induced tumor necrosis factor alpha production and not monocyte human leukocyte antigen-DR expression is correlated with survival in septic trauma patients. , 2006, Shock.

[128]  J. Moreau,et al.  Decrease in circulating dendritic cells predicts fatal outcome in septic shock , 2006, Intensive Care Medicine.

[129]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[130]  H. Volk,et al.  Impaired antigen presentation by human monocytes during endotoxin tolerance. , 2000, Blood.

[131]  Yan Yu,et al.  Association between regulatory T cell activity and sepsis and outcome of severely burned patients: a prospective, observational study , 2010, Critical care.